sanofi-adr (SNY) Key Developments
Innate Pharma S.A. Enters Collaboration Agreement with Sanofi on ADC Using Site-Specific Conjugation Tech
Apr 16 15
Innate Pharma SA announced that it has entered into a collaboration agreement with Sanofi to apply Innate Pharma's site-specific conjugation technology to the development of new Antibody Drug Conjugates or ADC. Sanofi-Aventis Recherche & Développement, the French R&D affiliate of Sanofi, will evaluate site-specific payload conjugation to enhance ADC pharmacokinetics, efficacy and safety and has the option to enter into a licencing agreement with Innate Pharma on this technology. Other terms of the agreement are undisclosed. Innate Pharma's coupling technology uses bacterial transglutaminase (BTG) enzyme. It aims to address the heterogeneity associated with traditional ADC coupling technologies which limits the therapeutic index of antibody conjugates. With Innate Pharma's technology, a single point mutation in the antibody's heavy chain generates either two or four specific enzyme-recognition sites, and linkers have been optimized to couple quantitatively at these positions.
Schrodinger Signs Drug Discovery Collaboration with Sanofi
Apr 7 15
Schrodinger signed a multi-year early drug discovery collaboration with Sanofi. Under the contract, Schrodinger will offer target analysis and validation to lead identification and lead optimisation for around ten drug discovery programmes. Schrodinger is to receive up to USD 120 million, which includes preclinical milestones. A new enterprise informatics system will also facilitate real-time collaboration between computational designers and medicinal chemists and will serve as the communications and project management platform for researchers across both firms.
Sanofi Announces Executive Changes
Apr 2 15
Sanofi has appointed Guido Businger as its new general director. Businger is replacing Fabrizio Guidi, who headed up Sanofi's subsidiary in Turkey. Businger, who has been working at Sanofi in Switzerland since 2004, was most recently head of the neurology division for Germany, Austria and Switzerland.
Ministry of Health Saudi Arabia Signs Cooperation Agreement with Sanofi
Mar 30 15
The Ministry of Health has entered into a cooperation agreement with Sanofi. The agreement is aimed at helping health care professionals with continuous training for diabetes education in primary care sector, medical research in the area of diabetes and good clinical practice (GCP) training program. Sanofi is partnering up with the MoH and other authorities focusing on continuous medical education for primary care physicians, medical research particularly in type 2 diabetes and GCP training program for health care professionals.
Selecta Biosciences, Inc., JDRF and Sanofi Extends Collaboration to Develop Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes
Mar 27 15
Selecta Biosciences, Inc., and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. This collaborative research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas. Selectas proprietary tolerogenic SVP products show potential to re-educate the immune system to stop or suppress pro-inflammatory responses against a specific antigen, thereby halting the undesirable immune reaction without causing harmful global immune suppression common with general immune system modulating drugs. As part of their collaboration, JDRF and Sanofi are co-financing the program with the aim of advancing the SVP product candidate to the clinic. This next phase of the SVP development program has been structured as a grant award to Selecta in order to test up to four antigens that may succeed in stopping the autoimmune response that destroys beta cells. JDRF has a strategic research plan designed to deliver a sustained stream of new, life-changing therapies.